Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471197 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01471197: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01471197 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01471197, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
Primary Outcome
Overall survival (OS) was defined as the time from the date of randomization until the date of death. For those participants who did not die by the time the study was terminated and last patient, last visit occurred, OS was censored (+) on the last date the participant was known to be alive. OS is presented below in increasing monthly categories of survival. OS analysis was to be performed when a total of approximately 132 deaths were observed but due to the early termination of the study, stati
Interventions
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Why NCT01471197 stopped before completion
NCT01471197 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01471197 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01471197 about?
NCT01471197 is a clinical study titled "Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer". The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
What is the current status of trial NCT01471197?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-07. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01471197?
The interventions under investigation include: Ipilimumab (BIOLOGICAL), Pemetrexed (BIOLOGICAL).
Who is sponsoring clinical trial NCT01471197?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01471197's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia